Lung Cancer

1

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

Kodityal, Sandeep, Elvin, Julia A., Squillace, Rachel, Agarwal, Nikita, Miller, Vincent A., Ali, Siraj M., Klempner, Samuel J., Ou, Sai-Hong Ignatius

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 406 KB

english, 2016

2

Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer

Malottki, Kinga, Popat, Sanjay, Deeks, Jonathan J., Riley, Richard D., Nicholson, Andrew G., Billingham, Lucinda

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 498 KB

english, 2016

3

Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15–19 in lung cancer

Krishnaswamy, Soundararajan, Mohammed, Abdul Khader, Amer, Osama E., Tripathi, Gyanendra, Alokail, Majed S., Al-Daghri, Nasser M.

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 1.77 MB

english, 2016

4

The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer

Guerrero, Eduardo, Ahmed, Merina

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 1.10 MB

english, 2016

5

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆

Hames, Megan L., Chen, Heidi, Iams, Wade, Aston, Jonathan, Lovly, Christine M., Horn, Leora

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 832 KB

english, 2016

6

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study

Smit, Egbert, Moro-Sibilot, Denis, Carpeño, Javier de Castro, Lesniewski-Kmak, Krzysztof, Aerts, Joachim, Villatoro, Rosa, Kraaij, Kees, Nacerddine, Karim, Dyachkova, Yulia, Smith, Karen T., Girvan, A

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 1.25 MB

english, 2016

7

Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma

Caumont, Charline, Veillon, Rémi, Gros, Audrey, Laharanne, Elodie, Bégueret, Hugues, Merlio, Jean-Philippe

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 1009 KB

english, 2016

8

Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer

Tsurugai, Yuichiro, Kozuka, Takuyo, Ishizuka, Naoki, Oguchi, Masahiko

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 1.27 MB

english, 2016

9

Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients

Kato, Tatsuya, Wada, Hironobu, Patel, Priya, Hu, Hsin-pei, Lee, Daiyoon, Ujiie, Hideki, Hirohashi, Kentaro, Nakajima, Takahiro, Sato, Masaaki, Kaji, Mitsuhito, Kaga, Kichizo, Matsui, Yoshiro, Tsao, Mi

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 2.68 MB

english, 2016

10

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC

Schmidt, L.H., Kuemmel, A., Schliemann, C., Schulze, A., Humberg, J., Mohr, M., Görlich, D., Hartmann, W., Bröckling, S., Marra, A., Hillejan, L., Goletz, S., Karsten, U., Berdel, W.E., Spieker, T., W

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 2.37 MB

english, 2016

11

Editorial Board

Journal:

Lung Cancer

Year:

2016

Language:

english

File:

PDF, 68 KB

english, 2016

Volume 92

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib

Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer

Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15–19 in lung cancer

The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study

Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma

Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer

Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC

Contents

Editorial Board